Following the market's gloomy 2022, this year has been a breath of fresh air with the S 500 rising 14% so far in 2023. Some biotech stocks have soared even higher thanks to strong products. Cystic fibrosis specialist Vertex Pharmaceuticals (NASDAQ: VRTX) has risen 19% in 2023, while cancer specialist (NASDAQ: EXEL) has gained 31% -- and both medical areas are likely to see strong demand for a long time to come.

Let's see why these two stocks could make good additions to investors' portfolios now.

Image source: Getty Images.

Continue reading

Source Fool.com